Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points

Fusco, Vittorio; Rossi, Maura; Fasciolo, Antonella; Gambino, Alessio; Palmeri, Serena

doi:10.1007/s00520-022-07214-z

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This error might lead not only to misguided recommendations, but also to practitioners underestimating the situation. However, patients with an underlying malignancy who do not receive a significantly higher drug dose because of metastasis to bone but receive adjuvant antiresorptive therapy to prevent or treat secondary osteoporosis are often overestimated [ 46 , 47 , 48 ].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Different Antibiotic Regimes for Preventive Tooth Extractions in Patients with Antiresorptive Intake—A Retrospective Cohort Study

et al. 2023

View full text Add to dashboard Cite

In the present study, the impacts on success rates between three different antibiotic regimes in patients receiving preventive tooth extraction during/after antiresorptive treatment were compared. For the retrospective analysis, we enrolled patients who had undergone tooth extraction from 2009 to 2019 according to the specified preventive conditions under antiresorptive therapy. Three antibiotic regimens were distinguished: (Group 1) intravenous for 7 days, (Group 2) oral for 14 days, and (Group 3) oral for 7 days of application. The primary endpoint was the occurrence of medication-related osteonecrosis of the jaw at 12 weeks after surgery. A total of 760 patients and 1143 extraction regions were evaluated (Group 1 n = 719; Group 2 n = 126; Group 3 n = 298). The primary endpoint showed no significant difference in the development of medication-related osteonecrosis of the jaw between the groups studied (Group 1 n = 50/669 (7%); Group 2 n = 9/117 (7%); Group 3 n = 17/281 (6%); p = 0.746). Overall, the success rate was 93% after intervention when preventive measures were followed. With the same success rate, a reduced, oral administration of antibiotics seems to be sufficient regarding the possible spectrum of side effects, the development of resistance and the health economic point of view.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Different Antibiotic Regimes for Preventive Tooth Extractions in Patients with Antiresorptive Intake—A Retrospective Cohort Study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…At present, long-term estimates of MRONJ are scanty in BM/ MM patients receiving monthly DMB injections (Fusco, Rossi, et al, 2022;Hata et al, 2022). Similarly, little data exist on the effect of cumulative dose of BMAs on the risk of MRONJ development in OP patients (Park et al, 2021).…”

Section: Medication-related Risk Factorsmentioning

confidence: 99%

Italian Position Paper (SIPMO-SICMF) on Medication-Related Osteonecrosis of the Jaw (MRONJ)

Bedogni

Mauceri²,

Fusco

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Despite being one of the most recently studied oral diseases, MRONJ remains a condition with uncertain and controversial issues. The aim of this updated version of the position paper on MRONJ developed by the Italian Societies of Oral Pathology and Medicine (SIPMO) and of Maxillofacial Surgery (SICMF) is to set forth an original interpretation of the current disputes on MRONJ. The Expert panel was appointed by the SIPMO and SICMF Board of Trustees in 2010 and comprised a multidisciplinary group of clinicians and researchers with recognized expertise in the field, who tracked the available literature and released two consecutive sets of Italian recommendations on MRONJ in 2013 and 2020. The advance of scientific knowledge and the perceived need for refinements to the previous position papers were recognized by the board panel who approved the submission of this updated version. This position paper highlights the current research status and provides a different perspective on several debated aspects of MRONJ including risk estimates, disease definition, diagnostic pathway, individual risk assessment, and the fundamental role of imaging in the diagnosis, classification, and management of MRONJ. The SIPMO-SICMF expert panel believes essential for the information provided to be disseminated to healthcare providers and patients at increased MRONJ risk. The SIPMO-SICMF Expert Panel recognizes that the statements and recommendations here provided warrant further confirmation and updates and highlight the need for a global and interdisciplinary scientific approach to MRONJ to overcome region-specific challenges.

show abstract

Italian position paper (SIPMO‐SICMF) on medication‐related osteonecrosis of the jaw (MRONJ)

Bedogni,

Mauceri,

Fusco

et al. 2024

Oral Diseases

View full text Add to dashboard Cite

ObjectiveThis paper aims to describe the 2023 update position paper on MRONJ developed by the Italian Societies of Oral Pathology and Medicine (SIPMO) and of Maxillofacial Surgery (SICMF).MethodsThis is the second update following the 2013 and 2020 Italian position papers by the Expert panel, which is a representation of the two scientific societies (SIPMO and SICMF).The paper is based on an extensive analysis of the available literature from January 2003 to February 2020, and the subsequent review of literature conducted between March 2020 and December 2022 to include all new relevant published papers to confirm or modify the previous set of recommendations.ResultsThis position paper highlights the main issues of MRONJ on risk estimates, disease definition, diagnostic pathway, individual risk assessment, and the fundamental role of imaging in the diagnosis, classification, and management of MRONJ.ConclusionThe Expert Panel confirmed the MRONJ definition, the diagnostic work‐up, the clinical‐radiological staging system and the prophylactic drug holiday, as recognized by SIPMO‐SICMF; while, it presented novel indications regarding the categories at risk of MRONJ, the prevention strategies, and the treatment strategies associated with the therapeutic drug holiday.

show abstract

Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points

Cited by 3 publications

References 10 publications

Comparison of Different Antibiotic Regimes for Preventive Tooth Extractions in Patients with Antiresorptive Intake—A Retrospective Cohort Study

Comparison of Different Antibiotic Regimes for Preventive Tooth Extractions in Patients with Antiresorptive Intake—A Retrospective Cohort Study

Italian Position Paper (SIPMO-SICMF) on Medication-Related Osteonecrosis of the Jaw (MRONJ)

Italian position paper (SIPMO‐SICMF) on medication‐related osteonecrosis of the jaw (MRONJ)

Contact Info

Product

Resources

About